Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia.
Ceftriaxone and cefoperazone monotherapy was compared in a multicentered, randomized, nonblinded, prospective study of patients with nosocomial pneumonia. These antibiotics were equally effective, with an overall successful treatment rate of 48 (80%) of 60 for the cefoperazone-treated patients and 35 (70%) of 50 for the ceftriaxone-treated patients. Patients with nursing-home-acquired pneumonia had similar bacterial pathogens and an almost identical cure rate to those patients with hospital-acquired infection. There was no statistical difference in the incidence of side effects of superinfections. The development of secondary pneumonia with resistant bacteria was low, 3% with cefoperazone and 4% with ceftriaxone. When antibiotic, administrative, and laboratory costs were calculated, cefoperazone was slightly less expensive than ceftriaxone. Both cefoperazone and ceftriaxone are effective therapy for the treatment of nosocomial pneumonia.
Mangi
R J
RJ
Hospital of St. Raphael, New Haven, CT 06544.
Peccerillo
K M
KM
Ryan
J
J
Berenson
C
C
Greco
T
T
Thornton
G
G
Andriole
V T
VT
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002438:Cefoperazone / Q000009:adverse effects / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000009:adverse effects / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D003428:Cross Infection / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D013183:Sputum / Q000382:microbiology; D015163:Superinfection / Q000209:etiology
D002443:Ceftriaxone; D002438:Cefoperazone